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Abstract
IMPORTANCE—Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic 
drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the 
optimal choice of the initial biologic therapy in previously untreated patients is unknown.
OBJECTIVE—To determine if the addition of cetuximab vsbevacizumab to the combination of 
leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, 
fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or 
metastatic KRAS wild-type (wt) colorectal cancer.
DESIGN, SETTING, AND PARTICIPANTS—Patients (≥18 years) enrolled at community and 
academic centers throughout the National Clinical Trials Network in the United States and Canada 
(November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer 
whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI 
regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or 
bevacizumab (n = 559). The last date of follow-up was December 15, 2015.
INTERVENTIONS—Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI 
chemotherapy regimen chosen by the treating physician and patient.
MAIN OUTCOMES AND MEASURES—The primary end point was overall survival. 
Secondary objectives included progression-free survival and overall response rate, site-reported 
confirmed or unconfirmed complete or partial response.
RESULTS—Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of 
patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving 
patients was 47.4 months (range, 0–110.7 months), and 82% of patients (938 of 1137) experienced 
disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy 
group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) 
of 0.88 (95% CI, 0.77–1.01; P = .08). The median progression-free survival was 10.5 months in 
the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group 
with a stratified HR of 0.95 (95% CI, 0.84–1.08; P = .45). Response rates were not significantly 
different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% 
CI, 1.0%-9.0%, P = .13).
CONCLUSIONS AND RELEVANCE—Among patients with KRAS wt untreated advanced or 
metastatic colorectal cancer, there was no significant difference in overall survival between the 
addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment.
TRIAL REGISTRATION—clinicaltrials.gov identifier: NCT00265850
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Colorectal cancer is the second leading cause of cancer death in North America. 
Fluorouracil became the only cytotoxic drug indicated for colorectal cancer in the 1990s1 
when the adoption of continuous infusion of this agent was found to have improved the 
median overall survival from 12 to 15 months.2 Since then, combination therapies of 
fluorouracil with leucovorin and either irinotecan (FOLFIRI regimen3) or oxaliplatin 
(mFOLFOX6 regimen4) were found to further improve survival and have become the main 
chemotherapeutic treatment options for colorectal cancer. A randomized crossover trial 
showed that these combination regimens were not statistically different, with patients 
receiving these agents in any sequence surviving a median 18 to 20 months.5,6
Cetuximab, a chimerized monoclonal antibody to the epidermal growth factor receptor 
(EGFR), was approved in combination with irinotecan or alone following irinotecan failure 
for patients with advanced or metastatic colorectal cancer whose tumors expressed EGFR.7 
Subsequent evidence indicated that cetuximab activity was unrelated to tumor expression of 
EGFR.8 Bevacizumab, a humanized murine antihuman vascular endothelial growth factor 
(VEGF) monoclonal antibody, was then approved for patients with advanced colorectal 
cancer in combination with fluorouracil-based chemotherapy.9 The addition of cetuximab or 
bevacizumab to cytotoxic chemotherapeutic combinations proved feasible and appeared to 
be more active than cytotoxic chemotherapies alone.10 These new options for patients with 
advanced or metastatic colorectal cancer raised the question of which was the optimal 
biologic monoclonal antibody-chemotherapy combination.
This trial was conducted to determine if the addition of cetuximab vs bevacizumab to the 
mFOLFOX6 regimen or the FOLFIRI regimen was superior as first-line therapy in advanced 
or metastatic KRAS wild-type (wt) colorectal cancer.
Methods
The Cancer and Leukemia B and Southwest Oncology Group 80405 trial was designed in 
collaboration with the National Cancer Institute (NCI) and was started in September 2005 to 
compare various combinations of chemotherapies and biologic therapies as first-line 
treatment of advanced and meta-static colorectal cancer: (1) chemotherapies plus cetuximab; 
(2) chemotherapies plus bevacizumab; and (3) chemotherapies plus cetuximab and 
bevacizumab (The study protocol is available in Supplement 1). Within 3 years, the lack of 
efficacy of EGFR antibodies in KRAS-mutant tumors11 and failures of the dual antibody and 
chemotherapy combination treatments12,13 resulted in a pivotal amendment restricting 
eligibility to patients with confirmed KRAS wt tumors and then later to closure of the dual 
antibody group. After 10 years and additional amendments a revised 2-group trial 
(cetuximab vs bevacizumab with chemotherapy regimens) completed patient enrollment and 
follow-up (see eTable 1 in Supplement 2).
In 2010, the Cancer and Leukemia B group became a part of the Alliance for Clinical Trials 
in Oncology (Alliance). This cooperative research group performed critical aspects of the 
present study: (1) captured the clinical data; (2) performed all statistical analyses; (3) 
provided data and safety monitoring for toxicity and for preplanned interim efficacy 
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analyses. The Southwest Oncology Group partner for the present study oversaw specimen 
biobanking and the distribution of samples to laboratory investigators.
Patient Eligibility
Institutional review board approval was required at all participating centers and all 
participating patients provided written informed consent. Patients were enrolled at centers 
across the National Cancer Trials Network in the United States and Canada. Eligible patients 
had pathology-documented untreated locally advanced or metastatic colorectal cancer, 
although measurable disease (tumor that could be quantified) was not require. Patients had 
to be candidates for either mFOLFOX6 or FOLFIRI regimens without known central 
nervous system metastases or grade II or greater peripheral neuropathy. In addition, 
hypertension had to be well controlled (blood pressure <160/90 mm Hg with treatment) and 
there could be no concurrent congestive heart failure. Therapeutic anticoagulation was 
permitted as long as the patient was therapeutic on a stable dose of anticoagulant. Patients 
with a significant bleeding event within 6 months of enrollment or a gastrointestinal 
perforation within 12 months of enrollment were excluded unless the perforated bowel 
segment had been resected. Up to 6 months of prior adjuvant treatment had to have 
concluded at least 12 months before recurrence. Prior radiotherapy to 5040 cGy was allowed 
but could not have encompassed more than 25% of bone marrow. Patients were excluded if 
they had undergone major surgery within the last 4 weeks or minor surgery within the last 2 
weeks.
National Cancer Institute trials are required to capture and report data on race/ethnicity. Data 
for patient covariates were captured in the NCI-standardized format and entered at the time 
of patient registration usually by a clinical research associate at the treating institution. Race/
ethnicity was determined by self-report.
Patients were 18 years or older with an Eastern Cooperative Oncology Group performance 
status of 0 to 1 and normal hepatic, renal, and hematologic laboratory values. Initially, 
enrolled patients could consent to the biomarker companion study (Cancer and Leukemia 
Group B 150506) and submit a specimen for EGFR status evaluation. In November 2008, 
KRAS wt (codons 12 and 13) became an eligibility criterion. In September 2009, the 
combined treatment group of both cetuximab and bevacizumab with chemotherapeutic 
regimen was discontinued. Patients in that treatment group were removed from the study, 
received treatment at the discretion of their physician, and were followed up per protocol. 
Patients enrolled and consented to the companion study whose tumor was KRAS wt and 
who received single antibody treatment were included in the primary cohort. Patients with 
KRAS mutant tumors were excluded from analysis but were given the option to continue 
taking the study treatment.
Following the amendment restricting eligibility to patients with KRAS wt tumors, patients 
consented to be tested for KRAS and agreed to submit 2 archival paraffin-embedded tumor 
tissue sections and 1 histology reference slide or 1 paraffin-embedded tumor block to the 
Southwest Oncology Group Solid Tumor Specimen Repository. Patients with KRAS wt 
tumors were offered registration and randomization whereas patients with mutant KRAS 
tumors were ineligible. In July 2010, eligibility could be determined by testing for KRAS 
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mutation in any Clinical Laboratory Improvement Amendments–certified laboratory, 
although specimen submission was mandated to confirm KRAS status by central review. 
Only patients with confirmed KRAS wt were included in this primary analysis. Following 
completion of the study, a subset of specimens were analyzed for expanded RAS status (see 
eMethods in Supplement 2 for KRAS and expanded RAS assays.)
Treatment
The choice of either the mFOLFOX6 or FOLFIRI chemotherapeutic regimen was made by 
the patient and physician prior to trial enrollment and randomization. From November 2005 
to September 2009 patients were randomized 1:1:1 to receive cetuximab, bevacizumab, or 
both of these biologic treatments in combination with either the mFOLFOX6 or FOLFIRI 
regimen. Thereafter, patients were randomized 1:1 to cetuximab or bevacizumab biologic 
treatment. At randomization, the primary physician indicated whether the treatment goal was 
palliative or potentially curative. Randomization was stratified by (1) chemotherapeutic 
regimen administered (mFOLFOX6; FOLFIRI), (2) receipt of prior adjuvant chemotherapy, 
and (3) prior pelvic radiation. Patients were stratified for statistical analysis by the time of 
enrollment either before or after the KRAS amendment. Treatment assignments were 
generated according to randomly permuted blocks within strata. A fixed-block size of 9 was 
used prior to the study amendment that stopped enrollment into the double-biologic group. 
Afterward, a block size of 6 was used.
Cetuximab or bevacizumab was administered prior to cytotoxic chemotherapies: 400 mg/m2 
of cetuximab was infused intravenously over 120 minutes on day 1, then 250 mg/m2 over 60 
minutes every week, and 5 mg/kg of bevacizumab was infused over 90 minutes in week one. 
Assuming no adverse reactions, subsequent infusions were administered over 30 to 60 
minutes every other week.
The FOLFIRI regimen was administered as 180 mg/m2 of irinotecan over 90 minutes and 
400 mg/m2 of leucovorin over 2 hours followed by a 400-mg/m2 bolus of fluorouracil, then 
a 2400-mg/m2 bolus of fluorouracil by a 46- to 48-hour infusion repeated every 2 weeks. 
The mFOLFOX6 regimen was administered as 85 mg/m2 of oxaliplatin over 120 minutes 
and 400 mg/m2 of leucovorin over 2 hours followed by a 400-mg/m2 bolus of fluorouracil 
then a 2400-mg/m2 bolus of fluorouracil by a 46- to 48-hour infusion repeated every 2 
weeks.
Patients received routine supportive care at the discretion of the treating physician. Standard-
dose adjustment criteria were applied to both mFOLFOX6 and FOLFIRI regimens. 
Treatment for the acneiform skin reaction was at the discretion of the treating physician. 
Patients experiencing oxaliplatin or other infusion reactions were not rechallenged with 
treatment. Adverse events were assessed using the NCI Common Toxicity Criteria version 
3.0.
Clinical Outcomes
The primary end point of overall survival was defined as time of study entry until death. 
Patients without reported deaths were censored at their last known follow-up. Secondary end 
points included response rate (site-reported confirmed or unconfirmed complete or partial 
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response by RECIST [Response Evaluation Criteria in Solid Tumors]) and progression-free 
survival measured from study entry until first documented progression or death. For the 
progression-free survival end point, patients alive without documented tumor progression 
were censored for progression at the most recent disease assessment. An additional 
secondary end point was 60-day mortality assessed as the proportion of patients dying due to 
any cause within 60 days of beginning protocol therapy. The incidence of arterial thrombotic 
events in each treatment group was monitored throughout the trial. Patients were evaluated 
every 8 weeks for response by conventional cross-sectional imaging using the RECIST v1.0 
criteria.14 Patients maintained their study treatment until disease progression, unacceptable 
toxic effects, a gap of more than 28 days between treatments, or decision to discontinue 
treatment. Disease assessment was done by the treating investigator and was not blinded.
Statistical Methods
The primary statistical analyses were 2-sided tests of superiority comparing cetuximab vs 
bevacizumab with regard to the primary and main secondary outcomes among patients 
whose tumors were determined to be KRAS wt (exon 2, codons 12,13) by Southwest 
Oncology Group review using intention-to-treat analyses. Sample-size calculations 
considered a median overall survival of 22.0 months with bevacizumab based on Hurwitz et 
al9 and a clinically meaningful difference of 5 to 6 months in median overall survival. The 
trial was designed to target a hazard ratio (HR) of 0.80 (an improvement from 22 to 27.5 
months) with 90% power (2-sided α = .05). Based on these factors, 1142 patients and 849 
primary outcome events were needed.
Interim analyses were conducted every 6 months after 15% of the expected number of 
overall survival outcome events were observed. The 2-sided Lan-DeMets analogue of 
O’Brien-Fleming boundaries was used to test the null hypothesis at each interim analysis 
according to the stratified log-rank test. Boundaries were truncated at 2.58; based on the 
actual boundaries used in the analyses, the 2-sided adjusted significance level at the final 
analysis was .06. A progression-free survival HR of 0.76 was detectable with 85% power 
based on a log-rank test (526 events; 2-sided α = .05). The Kaplan-Meier method was used 
to estimate overall and progression-free survival. The stratified log-rank test was used to 
compare overall survival between the bio-logics. No adjustments were made for multiple 
comparisons in the analysis of secondary end points. Thus, these analyses should be 
considered exploratory. Proportional hazards modeling was used to estimate HRs and 
associated 95% confidence intervals and to test interactions of sex, race (white vs nonwhite), 
and chemotherapy by treatment. Because white patients comprised 82% of the study sample, 
levels of race were collapsed to white vs nonwhite race for data analysis. Ethnicity was not 
considered other than descriptively. Hazard ratio estimates were adjusted for prior adjuvant 
therapy, prior radiotherapy, protocol chemotherapy, and randomization before and after the 
study was amended. Due to the large number of enrollment sites, this variable was not 
considered in the analysis. Subset analyses were conducted in the expanded RAS, 
mFOLFOX6, and FOLFIRI subgroups. In addition, κ statistics were used to estimate 
agreement between institutional and central review of KRAS status.
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Power was approximately 0.92 to detect a difference of 0.1 in the magnitude of response 
between treatment groups at the final analysis (2-sided α = .05). Within each treatment 
group, the hypothesis that the arterial thrombotic event rate was 0.5 or less was tested 
against the alternative, 0.08 or higher; 90% power was achieved to test this hypothesis (n = 
571; 1-sided α = .05). The lower 90% confidence bound estimate for the κ statistic was used 
to estimate assay agreement with 0.75 as a benchmark. Analyses are based on clinical data 
and patient follow-up as of December 15, 2015. Data collection and statistical analyses were 
conducted by the Alliance Statistics and Data Center (SAS v9.2, SAS Institute Inc; R 3.1.1, 
http://www.r-project.org). Data quality was reviewed and audited by the Alliance Statistics 
and Data Center and by the study chairperson following Alliance policies.
Results
From September 2005 to March 2012, 3058 patients were preregistered or registered, and 
2334 patients were randomized to 1 of 3 treatment groups at 396 study sites. Of these, 1137 
patients with confirmed KRAS wt tumors received bevacizumab (n = 559) or cetuximab (n = 
578). The 804 patients randomized after and the 333 patients registered before the KRAS 
amendment was implemented comprise the final primary analysis cohort (Figure 1). Data 
were released by the Alliance Data and Safety Monitoring Board in January 2014 after the 
11th interim analysis concluded with high probability that neither treatment group could 
meet the preplanned goal of a 5.5-month superior overall survival compared with the other. 
Results are reported for (1) the primary 2-group comparison between cetuximab and 
bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset 
described above; and (3) the chemotherapy subgroups.
Patient and tumor characteristics are presented in Table 1. The treatment groups were well-
balanced for age, sex, race, performance status, and site of primary tumor. Cure was the 
intent for 17.1% (99 of 578) of patients in the cetuximab group vs 13.2% (74 of 559) in the 
bevacizumab group. Ninety-six percent (1096 of 1137) of randomized patients with 
confirmed KRAS wt tumors started protocol therapy; 15 patients (1.1%) reported that they 
“withdrew prior to beginning protocol therapy” for an off-treatment reason: 7, bevacizumab; 
8, cetuximab (Figure 1). See treatment administration and dose modification summary for 
details (eTable 2 in Supplement 2).
Patient Outcome
All randomized patients with confirmed KRAS wt tumors were evaluated. Among 235 
patients enrolled with KRAS wt status by local assessment, 228 were confirmed by the 
Southwest Oncology Group (0.97; 95% CI, 0.94–0.99); the κ estimate for 239 patients with 
complete data was 0.52 with a 90% lower confidence bound estimate of 0.32. Of 1137 
patients, 874 (76.9%) patients died. Median follow-up for surviving patients (n = 263) was 
47.4 months (range, 0.0–110.7 months). Eighty-two percent of patients (938 of 1137) 
experienced disease progression. No significant differences were observed for either overall 
survival or progression-free survival in the primary analysis cohort. Median overall survival 
was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the 
bevacizumab-chemotherapy group (stratified HR, 0.88; 95% CI, 0.77–1.01; P = .08). 
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Median progression-free survival was 10.5 months in the chemotherapy-cetuximab group 
and 10.6 months in the chemotherapy-bevacizumab (stratified HR, 0.95; 95% CI, 0.84–1.08; 
P = .45; Figure 2 and eFigure 3 in Supplement 1). Response rates were 55.2% (309 of 559) 
in the bevacizumab group and 59.6% (345 of 578) in the cetuximab group (difference, 4.4%; 
95% CI, 1.0%–9.0%; χ2 P = .13).
The combination of chemotherapy and surgery rendered 140 patients disease free; median 
overall survival for the bevacizumab group was 62.2 months (95% CI, 49.4 months to not 
reached) and 64.7 months for the cetuximab group (95% CI, 51.6 months to not reached). 
Fifty-eight patients remained alive and disease free on the last data survey.
Post Hoc Analyses
Unplanned subgroup analyses were conducted for the expanded RAS, sex, race, and 
chemotherapy subsets. The results for overall survival (HR, 0.88; 95% CI, 0.72–1.08) and 
progression-free survival (HR, 1.03; 95% CI, 0.86–1.24) in the expanded RAS wt cohort 
were similar to those in the full cohort (Figure 2 and eFigure 3 in Supplement 2). Baseline 
characteristics were comparable between patients with and without expanded RAS results. 
No significant interactions were observed for sex (HR for interaction, 0.92; 95% CI, 0.70–
1.21) or race (HR for interaction, 1.04; 95% CI, 0.71–1.51) by biologic. A difference in 
overall survival was observed with mFOLFOX6 in favor of cetuximab (HR, 0.83; 95% CI, 
0.71–0.98; eFigure 4 in Supplement 2) but not with FOLFIRI, for which the HR for overall 
survival was 1.04 (CI 95%, 0.79–1.35). The chemotherapy by biologic interaction HR for 
overall survival was 1.27 (95% CI, 0.94–1.73; P for interaction, .11; eFigures 4 and 5 in 
Supplement 2).
Adverse Events
Among 1137 patients, 1092 patients (96%) reported at least 1 adverse event: 584 patients 
(53%) experienced grade 3 or higher and 153 (14%) experienced grade 4 or higher adverse 
events. Thirty-one patients died while receiving the protocol therapy: 16, bevacizumab; 15, 
cetuximab. The deaths of 8 patients in the bevacizumab group and 7 in the cetuximab group 
could possibly be related to the protocol treatment. Adverse events reported in at least 10% 
of patients were not different across groups (Table 2). Toxic effects that were lower than 
grade 3 were distinct with acneiform rash predominating for cetuximab and hypertension 
predominating for bevacizumab. The rate of arterial thrombotic events was not statistically 
higher than 5% on either regimen. No significant difference in 60-day mortality was 
observed (1.4% [8 of 555] for bevacizumab; 2.0% [12 of 571] for cetuximab (Fisher exact 
test, P = .50).
Discussion
In this clinical trial involving patients with advanced or meta-static KRAS wt colorectal 
cancer, there was no significant difference in overall survival with treatment using cetuximab 
vs bevacizumab added to the mFOLFOX6 or FOLFIRI chemotherapeutic regimens as first-
line treatments. These findings persisted following exclusion of patients with any RAS 
mutations.
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When planning this randomized clinical trial, a 22-months’ median survival was expected 
for the combination of bevacizumab and the chemotherapeutic regimen, yet survival was at 
least 29 months in both groups. Better chemotherapeutic regimens, patient selection, and 
changing multidisciplinary management likely contributed to these outcomes as did the 
exclusion of patients with KRAS mutations. This eligibility change increased the proportion 
of study patients who might benefit from cetuximab but also improved the prognosis for the 
entire group by eliminating patients with negatively prognostic RAS mutations. Also, 
patients in this study likely had lower tumor burden compared with patients who participated 
in earlier studies as a result of better imaging at diagnosis as well as the coincidental 
detection of small cancers when patients undergo diagnostic imaging for other indications. 
The majority of patients also had access to both cetuximab and bevacizumab at progression 
because each biologic therapy was commercially available. Patients who received any 
subsequent treatment could have changed chemotherapy and either crossed over to or 
continued with bevacizumab beyond tumor progression.15 Twelve percent of patients were 
rendered temporarily disease free (41% remained without evidence of cancer at a median of 
5.5 years’ follow-up) with surgery of all sites of disease. This also contributed to the survival 
results. In addition, some patients may have benefitted from subsequent experimental or off-
label treatments,
These results differ from 2 smaller but contemporary studies that asked a similar question. 
First, the FIRE-3 trial (n=592) led by the Arbeitsgemeinschaft Internistische Onkologie 
cooperative group (AIO)16 also compared cetuximab and bevacizumab but differed from the 
present study in that the chemotherapy was limited to FOLFIRI and the primary outcome 
was investigator-adjudicated response rate. This trial found no significant difference in 
response rate (62% vs 58%, P = .18) between cetuximab and bevacizumab biologic 
therapies. However, overall survival favored cetuximab by 3.7 months (28.7 vs 25.0 months) 
and was even more favorable with expanded RAS analysis (33.1 vs 25.6 months; P = .011). 
Second, the PEAK (Panitumumab Efficacy in Combination With mFOLFOX6 Against 
Bevacizumab Plus mFOLOFOX6 in mCRC Subjects With Wild-Type KRAS Tumors) trial17 
enrolled 285 patients but compared panitumumab (a fully humanized anti-EGFR antibody) 
to bevacizumab in combination with FOLFOX. The primary outcome of progression-free 
survival was not statistically different between the panitumumab and bevacizumab treatment 
groups (10.9 vs 10.1 months, P = .35). However, there was a significant difference in overall 
survival between panitumumab and bevacizumab (34.2 vs 24.3 months; P = .009).
Neither of these studies mandated subsequent treatment choices (although FIRE-3 had 
recommended specific second-line treatments per protocol). Furthermore, the variances in 
management preferences across the world can have important effects on overall survival. 
The FIRE-3 investigators made an effort to document subsequent treatments and postulated 
that patients receiving first-line cetuximab treatment would have better overall survival 
because of a biological advantage when an EGFR inhibitor is followed by bevacizumab.18 
However, a poorer overall survival for patients receiving bevacizumab in FIRE-3 compared 
with this study accounts for most of the survival difference (expanded RAS, chemotherapy + 
bevacizumab, overall survival for 80405 was 31.2 months; for FIRE-3,25.6 months). The use 
of bevacizumab beyond progression after FOLFIRI and bevacizumab18 in patients in the 
FIRE-3 study (11% of the 68% of patients who received any second-line treatment) is 
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infrequent compared with its routine use in the United States. This is speculative, however, 
because the collection of subsequent treatment details across hundreds of sites in North 
America is extremely difficult and the details of such data would be open to questioning no 
matter the resources put into such an effort. Therefore, the sequencing theory promulgated 
by FIRE-3 investigators is not addressed.
This study has several limitations. First, the imbalance in choice of mFOLFOX6 vs 
FOLFIRI regimens limits the ability to statistically compare the cytotoxic chemotherapy 
regimens and any possible interaction with the antibodies. Second, this study only mandated 
first-line treatment with patients who at any time went more than 28 days without treatment 
being removed from study. Because treatment holidays were used more commonly during 
the course of the study and because collection of the details of treatment drugs and 
schedules, dosing and complications has been challenging, it is difficult to infer the effects 
of subsequent management decisions. Third, one element not included in the on-study 
information was primary cancer site (eg, right vs left colon). This information was collected 
post hoc through chart review and has been suggested to influence outcome as a biologic 
surrogate.19
Conclusions
Among patients with KRAS wt untreated advanced or meta-static colorectal cancer, there 
was no significant difference in overall survival between the addition of cetuximab vs 
bevacizumab to chemotherapy as initial biologic treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
Question
Does the addition of cetuximab with a combination chemotherapeutic regimen improve 
overall survival compared with the addition of bevacizumab with a combination 
chemotherapeutic regimen as the initial treatment for patients with advanced or 
metastatic colorectal cancer who have KRAS wild-type tumors?
Findings
In this randomized clinical trial involving 1137 patients, there was no significant 
difference in overall survival among patients treated with either leucovorin, fluorouracil, 
and oxaliplatin (mFOLFOX6) or leucovorin, fluorouracil, and irinotecan (FOLFIRI) and 
then randomized to receive cetuximab or bevacizumab.
Meaning
Neither biologic monoclonal antibody demonstrated significantly greater overall survival 
for initial treatment of advanced or metastatic colorectal cancer.
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Figure 1. Flow of Patients Through Cancer and Leukemia B Group and Southwest Oncology 
Group 80405 Trial
a
 The reasons patients with wild-type (wt), indeterminate, or unknown KRAS status were 
excluded were not captured at the time of exclusion.
b
 Amendment 5 limited trial eligibility to only patients with KRAS wild-type colorectal 
cancer in November 2008.
c
 This double-biologic treatment group was dropped from the trial and primary analysis 
based on amendment 6, which was established September 2009.
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d
 The primary cohort comprises patients whose KRAS wt colorectal cancer was centrally 
confirmed by the Southwest Oncology Group and who had consented for the use of their 
specimens.
e
 Reasons for ineligibility in the primary cohort were not captured.
f
 Forty-nine tumor samples lacked sufficient DNA or analyses were incomplete.
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Figure 2. Kaplan-Meier Estimates of Overall Survival Among Patients Randomized to 
Bevacizumab or Cetuximab
Tick marks on the curves denote the last known follow-up time for patients with no death 
date reported. The hazard ratio and P value are adjusted for prior adjuvant therapy, prior 
radiotherapy, protocol chemotherapy, and randomization before and after the amendment 
restricting eligibility to the KRAS wild-type tumor. Hazard ratio and P value for the RAS 
analysis are adjusted for prior adjuvant therapy, prior radiotherapy, protocol chemotherapy, 
and randomization before or after the amendment restricting eligibility to KRAS wild type 
tumor (KRAS is defined as exon 2 codons 12, 13; exon 4, codons 117, 146; exon3 codons 
59, 61 or NRAS: exon 2 codons 12, 13; exon 3 codons 59, 61; exon 4 codons 117, 146).
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Table 1
Patient and Tumor Characteristics by Treatment for Patients With KRAS Wild-Type (codons 12, 13) 
Metastatic Colorectal Cancer
Characteristic
No. (%) of Patients
Chemotherapy +
Bevacizumab
(n = 559)
Chemotherapy +
Cetuximab
(n = 578)
Total
(N = 1137)
Age, median (range), y 59.0 (21.8–85.0) 59.2 (20.8–389.5) 59.1 (20.8–89.5)
Men 348 (62.3) 349 (60.4) 697 (61.3)
Women 211 (37.7) 229 (39.6) 440 (38.7)
Race
  Unknown 13 (2.3) 16 (2.8) 29 (2.6)
  White 465 (83.2) 469 (81.1) 934 (82.1)
  Black 64 (11.4) 65 (11.2) 129 (11.3)
  Asian 13 (2.3) 22 (3.8) 35 (3.1)
  Native Hawaiian or Pacific Islander 0 3 (0.5) 3 (0.3)
  American Indian or Alaska Native 3 (0.5) 3 (0.5) 6 (0.5)
  Not reported 1 (0.2) 0 (0.0) 1 (0.1)
Ethnicity
  Hispanic or Latino 35 (6.3) 37 (6.4) 72 (6.3)
  Non-Hispanic 495 (88.6) 519 (89.8) 1014 (89.2)
  Not reported 2 (0.4) 1 (0.2) 3 (0.3)
  Unknown 27 (4.8) 21 (3.6) 48 (4.2)
Eastern Cooperative Oncology Group Performance Statusa
  0 324 (58.0) 333 (57.6) 657 (57.8)
  1 233 (41.7) 245 (42.4) 478 (42.0)
  2 2 (0.4) 0 2 (0.2)
Tumor biology
  Metachronous (metastasis subsequent to diagnosis of primary tumor) 112 (20.0) 124 (21.5) 236 (20.8)
  Synchronous (metastases present at diagnosis of primary tumor) 445 (79.6) 447 (77.3) 892 (78.5)
  Unknown 2 (0.4) 7 (1.2) 9 (0.8)
Colorectal tumor location
  Left 334 (59.7) 355 (61.4) 689 (60.6)
  Right 142 (25.4) 138 (23.9) 280 (24.6)
  Transverse 31 (5.5) 31 (5.4) 62 (5.5)
  Multiple 0 1 (0.2) 1 (0.1)
  Unknown 52 (9.3) 53 (9.2) 105 (9.2)
Primary tumor unresected at study entry
  No 409 (73.1) 436 (75.4) 845 (74.3)
  Yes 150 (26.8) 142 (24.5) 292 (25.7)
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Characteristic
No. (%) of Patients
Chemotherapy +
Bevacizumab
(n = 559)
Chemotherapy +
Cetuximab
(n = 578)
Total
(N = 1137)
Protocol chemotherapy
  mFOLFOX6 409 (73.2) 426 (73.7) 835 (73.4)
  FOLFIRI 150 (26.8) 152 (26.3) 302 (26.6)
Prior pelvic radiation
  No 509 (91.1) 526 (91.0) 1035 (91.0)
  Yes 50 (8.9) 52 (9.0) 102 (9.0)
Prior adjuvant chemotherapy
  No 478 (85.5) 499 (86.3) 977 (85.9)
  Yes 81 (14.5) 79 (13.7) 160 (14.1)
Disease description
  Missing 5 (0.9) 4(0.7) 9 (0.8)
  Locally advanced 14 (2.5) 12 (2.1) 26 (2.3)
  Metastatic 540 (96.6) 562 (97.2) 1102 (96.9)
Intent of treatment
  Missing 17 (3.0) 18 (3.0) 35 (3.1)
  Palliative 468 (83.7) 461 (79.7) 929 (81.7)
  Curative intent 74 (13.3) 99 (17.3) 173 (15.2)
Metastatic sitesb
  Primary site or tumor bed 161 (29.1) 136 (23.7) 297 (26.3)
  Intra-abdominal 127 (22.9) 134 (23.3) 261 (23.1)
  Bone 16 (2.9) 17 (3.0) 33 (2.9)
  Lung 182 (32.9) 185 (32.2) 367 (32.5)
  Any liver 411 (74.2) 421 (73.3) 832 (73.8)
  Liver only 165 (29.5) 187 (32.3) 352 (30.9)
  Central nervous system including brain 0 1 (0.2) 1 (0.1)
  Other 92 (16.6) 92 (16.0) 184 (16.3)
Abbreviations: FOLFIRI, leucovorin, fluorouracil, and irinotecan; mFOLFOX6, leucovorin, fluorouracil, and oxaliplatin.
a
The 0-to-5 coded scale describing patient daily level of functioning from fully active (0) to completely disabled (4); dead (5). As published in 
Oken et al.24
bSites are not mutually exclusive except for “Liver only.”
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Table 2
Grade 3 or More Adverse Events at Least Possibly Related to Treatment and Occurring in at Least 10% of 
Patients in Either Treatment Group (Maximum Grade per Patient per Event)
No.(%)
Chemotherapy
+ Bevacizumab
(n = 539)
Chemotherapy +
Cetuximab
(n = 553)
Hematologic Adverse Events
Blood or bone marrow, gradea
  3 125 (23) 137 (25)
  4 35 (6) 37 (7)
  5 0 0
Nonhematologic Adverse Events
Fatigue (asthenia, lethargy, malaise), gradeb
  3 39 (7) 49 (9)
  4 4 (1) 3 (1)
  5 0 0
Diarrhea, gradeb
  3 45 (8) 60 (11)
  4 1 (<1) 0
  5 0 0
Sensory neuropathy, gradeb
  3 72 (13) 73 (13)
  4 3 (1) 0
  5 0 0
aGrade 3 indicates absolute neutrophils count of less than 1000/µL to 500/µL or absolute granulocytes count of less than 1.0 × 109/L to 0.5 × 
109/L; grade level 4, absolute neutrophils count of less than 500/µL or absolute granulocytes count of less than 0.5 × 109/L; and grade level 5, 
death.
bGrade 3 indicates severe; grade 4, life threatening; and grade 5, death.
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